BACKGROUND AND AIMS: The purpose of the present trial was to clarify the efficacy of postoperative adjuvant chemotherapy including an oral fluoropyrimidine anticancer drug, the 1-hexylcarbamoyl-5-fluorouracil (HCFU), for the treatment of colon cancer. METHOD:Patients with clinical stage Dukes' B and C colon cancer, who had been treated surgically, were assigned to a chemotherapy group treated with mitomycin C, 5-fluorouracil (5-FU), and HCFU and to a control group that received no postoperative adjuvant chemotherapy. RESULTS: Of the 1,001 patients registered for the study, 17 (1.7%) were ineligible. The incidence of toxicity was significantly higher in the chemotherapy group than in the control group. However, there were few severe side effects and no deaths related to the treatment. Overall survival showed no significant difference between the groups. The disease-free survival or the recurrence-free intervals was significantly higher in the chemotherapy group than in the control group. The incidence of hepatic recurrence was significantly (P=0.003) lower in the chemotherapy group than in the control group. CONCLUSION: The results of this study demonstrated the efficacy of adjuvant chemotherapy for colon cancer, i.e., combined chemotherapy that included the 5-FU oral anticancer drug HCFU.
RCT Entities:
BACKGROUND AND AIMS: The purpose of the present trial was to clarify the efficacy of postoperative adjuvant chemotherapy including an oral fluoropyrimidine anticancer drug, the 1-hexylcarbamoyl-5-fluorouracil (HCFU), for the treatment of colon cancer. METHOD:Patients with clinical stage Dukes' B and C colon cancer, who had been treated surgically, were assigned to a chemotherapy group treated with mitomycin C, 5-fluorouracil (5-FU), and HCFU and to a control group that received no postoperative adjuvant chemotherapy. RESULTS: Of the 1,001 patients registered for the study, 17 (1.7%) were ineligible. The incidence of toxicity was significantly higher in the chemotherapy group than in the control group. However, there were few severe side effects and no deaths related to the treatment. Overall survival showed no significant difference between the groups. The disease-free survival or the recurrence-free intervals was significantly higher in the chemotherapy group than in the control group. The incidence of hepatic recurrence was significantly (P=0.003) lower in the chemotherapy group than in the control group. CONCLUSION: The results of this study demonstrated the efficacy of adjuvant chemotherapy for colon cancer, i.e., combined chemotherapy that included the 5-FU oral anticancer drug HCFU.
Authors: E Van Cutsem; C Pozzo; H Starkhammar; L Dirix; E Terzoli; F Cognetti; Y Humblet; C Garufi; L Filez; G Gruia; C Cote; C Barone Journal: Ann Oncol Date: 1998-11 Impact factor: 32.976
Authors: P M Hoff; R Ansari; G Batist; J Cox; W Kocha; M Kuperminc; J Maroun; D Walde; C Weaver; E Harrison; H U Burger; B Osterwalder; A O Wong; R Wong Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper Journal: J Clin Oncol Date: 2001-11-01 Impact factor: 44.544
Authors: P Rougier; E Van Cutsem; E Bajetta; N Niederle; K Possinger; R Labianca; M Navarro; R Morant; H Bleiberg; J Wils; L Awad; P Herait; C Jacques Journal: Lancet Date: 1998-10-31 Impact factor: 79.321
Authors: Cyntanna C Hawkins; Amber B Jones; Emily R Gordon; Sarah E Williford; Yuvika Harsh; Julia K Ziebro; Catherine J Landis; Sajina Gc; David K Crossman; Sara J Cooper; Sasanka Ramanadham; Ninh Doan; Anita B Hjelmeland Journal: Cells Date: 2022-06-09 Impact factor: 7.666
Authors: Yedda Li; Yue Xu; Bruno A Benitez; Murtaza S Nagree; Joshua T Dearborn; Xuntian Jiang; Miguel A Guzman; Josh C Woloszynek; Alex Giaramita; Bryan K Yip; Joseph Elsbernd; Michael C Babcock; Melanie Lo; Stephen C Fowler; David F Wozniak; Carole A Vogler; Jeffrey A Medin; Brett E Crawford; Mark S Sands Journal: Proc Natl Acad Sci U S A Date: 2019-09-16 Impact factor: 11.205
Authors: Ninh B Doan; Hisham Alhajala; Mona M Al-Gizawiy; Wade M Mueller; Scott D Rand; Jennifer M Connelly; Elizabeth J Cochran; Christopher R Chitambar; Paul Clark; John Kuo; Kathleen M Schmainda; Shama P Mirza Journal: Oncotarget Date: 2017-11-07